Relapse-free survival and overall survival of 727 granulomatosis with polyangiitis patients according to ANCA specificity
| Overall n=727 | P value (PR3-ANCA+ vs MPO-ANCA+ vs ANCA–) | No ANCA n=62 | P value (ANCA– vs PR3-ANCA+ and MPO-ANCA+) | MPO-ANCA+ n=119 | P value (MPO-ANCA+ vs PR3-ANCA+ and ANCA–) | PR3-ANCA+ n=546 | P value (PR3-ANCA+ vs MPO-ANCA+ and ANCA–) | |
| Relapse-free survival | ||||||||
| 5-year (95% CI) | 38.6% (34.3 to 43.4) | 0.12 | 56.2% (43.8 to 72.1) | 0.18 | 47.2% (36.0 to 61.7) | 0.17 | 35.4% (30.7 to 40.9) | 0.04 |
| 10-year (95% CI) | 19.4% (14.7 to 25.5) | 37.0% (22.7 to 60.2) | 32.7% (20.5 to 52.0) | 14.8% (10.0 to 21.9) | ||||
| Overall survival | ||||||||
| 5-year (95% CI) | 92.6% (90.3 to 95.0) | 0.0058 | 93.0% (86.6 to 89.9) | 0.92 | 83.9% (75.2 to 93.5) | 0.001 | 94.2% (91.8 to 96.7) | <0.01 |
| 10-year (95% CI) | 86.8% (82.9 to 90.9) | 85.7% (75.0 to 98.0) | 81.5% (72.1 to 92.1) | 88.1% (83.5 to 92.9) | ||||
ANCA, antineutrophil cytoplasm antibody; MPO, myeloperoxidase; PR3, proteinase-3.